Absci Quarterly Cash Flow Statement
NASDAQ: ABSIHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Pre-market: 10.12 -0.39%
Absci free cash flow
In the quarter ended Jun 30, 2026, Absci generated -$27.6 million of operating cash flow and spent $1,000 on capital expenditures. That left free cash flow of -$27.6 million, a free-cash-flow margin of -8668.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Absci cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -33.21M | -29.60M | -29.56M | -28.71M | -30.57M | -26.35M | -28.98M | -27.40M | -24.75M | -21.98M | -23.55M | -21.99M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.70M | 2.73M | 2.83M | 2.84M | 3.00M | 3.07M | 3.23M | 3.35M | 3.38M | 3.42M | 3.48M | 3.51M |
| Stock-Based Compensation | 5.24M | 4.38M | 4.26M | 4.40M | 4.75M | 4.91M | 5.07M | 5.50M | 5.29M | 3.59M | 3.18M | 2.54M |
| Change in Working Capital | -1.61M | -2.98M | 495.00K | -4.07M | 6.97M | -2.66M | 2.91M | -3.62M | -755.00K | 1.92M | 3.53M | 1.18M |
| Operating Cash Flow | -27.56M | -26.31M | -29.18M | -25.03M | -16.87M | -21.84M | -16.96M | -20.73M | -16.84M | -17.86M | -14.92M | -10.36M |
| Capital Expenditures | -1.00K | -30.00K | 103.00K | -962.00K | -223.00K | -25.00K | -23.00K | -48.00K | -333.00K | 0 | -17.00K | -307.00K |
| Investing Cash Flow | 24.07M | 7.36M | 19.55M | -63.70M | 9.04M | -15.04M | 19.04M | 14.81M | 1.25M | -76.68M | 18.96M | 20.14M |
| Debt Repaid | -263.00K | -460.00K | -498.00K | -776.00K | -1.08M | -762.00K | -899.00K | -816.00K | -801.00K | -872.00K | -844.00K | -761.00K |
| Financing Cash Flow | 102.73M | 7.56M | 3.84M | 60.32M | -1.00M | 42.79M | 986.00K | 490.00K | -134.00K | 81.18M | -1.24M | -924.00K |
| Net Change in Cash | 99.23M | -11.39M | -5.79M | -28.42M | -8.84M | 5.91M | 3.06M | -5.44M | -15.72M | -13.36M | 2.80M | 8.85M |
| Free Cash Flow | -27.57M | -26.34M | -29.08M | -25.99M | -17.10M | -21.86M | -16.99M | -20.78M | -17.18M | -17.86M | -14.94M | -10.67M |
This table shows 12 quarterly periods of Absci's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ABSI's reporting calendar. What is a cash flow statement?